Early-onset colorectal cancer on the rise, Europe OKs expanded use of Stelara — top stories in gastroenterology
Study results recently showed an increasing incidence of colorectal cancer among young adults in nine high-income countries. Also, the European Commission approved the expanded use of Stelara for adults with moderately to severely active ulcerative colitis.
These topics and more are among the top stories in gastroenterology.
‘We should be unsettled’: Colorectal cancer incidence rising among young adults
Researchers from the American Cancer Society have found increasing incidence of colorectal cancer among young adults in nine high-income countries where population-based screening initiatives have led to stabilized or decreasing trends among older adults, according to study results published in Gut. Read more.
European Commission approves expanded use of Stelara for moderately to severely active ulcerative colitis
The European Commission approved the expanded use of Stelara for adults with moderately to severely active ulcerative colitis, according to a company press release. Read more.
Q&A: Text message system improves colonoscopy adherence
Despite all the dangers involved with colorectal cancer, many people do not keep up to date with recommended colonoscopy screening. About one-third of individuals are behind. With so many barriers and difficulties in place, researchers are left to find ways to make getting patients to colonoscopy easier. Read more.
Women with inflammatory bowel disease have reduced fertility
Women with inflammatory bowel disease have an increased time to pregnancy, which indicates reduced fertility among that population, according to study results. Read more.
Indefinite dysplasia in inflammatory bowel disease increases advanced neoplasia risk
For patients with inflammatory bowel disease who were undergoing surveillance for colorectal neoplasia, indefinite dysplasia was associated with an increased risk for the development of advanced colorectal neoplasia, according to study results. Read more.